Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Tiribelli, Mario;Capodanno, Isabella;Miggiano, Maria Cristina;Bucelli, Cristina;Cavazzini, Francesco;Leonetti Crescenzi, Sabrina;Russo, Sabina;Scalzulli, Emilia;Bernardelli, Andrea;Luciano, Luigiana;Mulas, Olga;Loglisci, Giuseppina;Elena, Chiara;Pizzano, Umberto;Attolico, Immacolata;Binotto, Gianni;Crisà, Elena;Sportoletti, Paolo;Di Veroli, Ambra;Scortechini, Anna Rita;Leporace, Annapaola;Basile, Maria;Crugnola, Monica;Stagno, Fabio;Murgano, Pamela;Rapezzi, Davide;Malato, Alessandra;Pizzuti, Michele;Luzi, Debora;Trawinska, Malgorzata Monika;Iurlo, Alessandra;Bocchia, Monica;Fava, Carmen;Caocci, Giovanni;Bonifacio, Massimiliano;Saglio, Giuseppe Nicola;Specchia, Giorgina;Breccia, Massimo;Latagliata, Roberto

2021-01-01

---

Abstract

Tyrosine kinase inhibitors (TKIs) revolutionized treatment of chronic myeloid leukemia (CML). However, the rst months of therapy are crucial, as optimal response is dened as the achievement of molecular milestones at 3, 6 and 12 months (mo.) and as many toxicities, also causing a TKI switch, are more frequent in the 1st year